According to international guidelines and current literature, patients with luminal-like breast cancer (HER2 negative, ER+) could benefit from neoadjuvant endocrine therapy (14) as a safe and effective option that would allow them to temporarily delay surgery and outpatient visits. Here, ERBB2 is linked to breast cancer.